Welcome to the 5th Chronic Kidney Disease Drug Development Summit
Putting a spotlight on untapped pathways for therapeutic intervention, establishing a well-defined pathway in rare disease, and constructing robust clinical programs to shorten clinical trials, the CKD Drug Development Summit is uniquely positioned to de-risk drug development in cardiorenal disorders and provide strategic insight into paving the way to regulatory approval.
Hear from industry experts unravelling complex disease pathogenesis, demonstrating efficacy with real-world evidence and earlier biomarkers, and executing trials in pediatric patient populations to bring effective therapies to patients faster.
Define the next step in employing and validating biomarkers such as eGFR, PROs, real-world evidence and more in clinical trials with FDA, the University of Groningen, and Bayer to move beyond hard endpoints and demonstrate efficacy
Forge a deeper understanding of multifactorial pathogenesis of rare and chronic kidney diseases and interrogate the interrelationships between cardiorenal and metabolic disorders with Johnson & Johnson, Novo Nordisk, and Eli Lilly to investigate exciting opportunities for therapeutic intervention
Reimagine patient inclusion and exclusion criteria through strategic consideration of disease stage, pediatric patients, transplant patients, and comorbidities with Chinook, Otsuka, and Q32 Bio to transform patient recruitment
Navigate exciting progress in rare diseases including IgAN, FSGS, Lupus Nephritis, aHUS, and CG3 with Sanofi, Kira Pharmaceuticals, and Travere to pioneer trial design in small patient populations and elucidate opportunities for indication expansion
De-risk the transition from proof of concept to the clinic through robust selection of preclinical models and early understanding of efficacy with Goldfinch Bio, Boehringer Ingelheim, and CSL Vifor to recapitulate complex kidney biology and monitor treatment effect